Mizuho cuts Zscaler stock price target on guidance concerns By Investing.com

Zscaler reported fiscal Q3 revenue of $850.48 million and EPS of $1.08, both above consensus, with annual recurring revenue up 25% year over year and gross margin at 76.6%. However, Mizuho cut its price target to $185 from $210 and highlighted weaker-than-expected fiscal Q4 and fiscal 2027 guidance amid sales leadership departures and uncertainty around new product uptake. The stock remains well positioned in SASE and Zero Trust, but near-term sentiment is tempered by slower forward growth expectations and multiple analyst target cuts.

Analysis

ZS is still a quality compounder, but the market is starting to price in a lower probability that its current growth algorithm is fully repeatable. The key second-order issue is not the quarter itself; it is the mix shift behind it: if a meaningful share of incremental ARR came from less durable geographies or public-sector demand, the multiple should compress because the business is no longer being valued as a clean, high-visibility land-grab. That matters because software names at this growth rate are typically supported by confidence in durable net-new ARR, and any perception of “borrowed” growth can de-rate the stock faster than modest forecast cuts imply.

The bigger catalyst risk is organizational, not competitive: sales leadership turnover can create a 2-3 quarter lag in pipeline conversion before it shows up in reported ARR. That means the next two prints are more important than the current one, since an unchanged macro backdrop could still produce decelerating bookings if quota-carrying coverage and channel execution reset. In cybersecurity, execution slippage tends to benefit adjacent platform vendors first, not just direct peers, because customers prefer consolidating around the vendor that looks most operationally stable.

Consensus appears to be missing how sensitive the multiple is to guidance credibility, especially when the company is still priced for premium durability. The stock can look cheap on outer-year FCF, but that is only relevant if growth does not step down materially; if FY27 growth settles into the mid-teens, the market can easily re-rate ZS from a “growth compounder” to a “cash-flow story,” which implies several turns of multiple compression rather than incremental downside. On the flip side, if management stabilizes the sales bench and new products start contributing within the next 1-2 quarters, the selloff may overshoot and set up a strong reversal because the long-term SASE/Zero Trust thesis remains intact.

Key Decisions for Investors

• Short ZS into strength over the next 2-6 weeks, using any relief rally toward prior support as the entry: the near-term risk/reward favors fading multiple expansion until the market sees one clean post-turnover print.
• Pair trade: long CRWD / short ZS for 1-2 quarters, expressing preference for the more stable execution profile in cybersecurity while isolating ZS-specific sales-transition risk.
• Buy ZS Jan-2026 put spreads, targeting a move to the low-$140s if the market continues to de-rate FY27 growth expectations; defined risk is preferable given the stock can snap back on any guidance stabilization.
• For long-only managers, wait for evidence of pipeline re-acceleration before adding: a better entry is after the next earnings cycle if organic net-new ARR re-accelerates, not on valuation alone.